secwatch.observer — SEC 8-K summary
======================================

Issuer:     HCW Biologics Inc. (HCWB)
CIK:        0001828673
Form:       8-K
Filed at:   2023-11-14T23:59:59+00:00
Accession:  0000950170-23-063348
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

HCW Biologics Q3 net loss widens to $4.9M; cash $11.2M; Phase 1 data positive
-----------------------------------------------------------------------------

- Revenue fell to $853K from $1.8M YoY; licensee Wugen limiting purchases for remainder of 2023.
- Net loss increased 26% YoY to $4.9M; G&A jumped 107% to $3.6M due to Altor/NantCell litigation legal fees.
- Cash and equivalents $11.2M at Sep 30, 2023; company believes capital sufficient through end of 2024.
- Phase 1 trial of HCW9218: 50% of evaluable patients had stable disease; dose-dependent TGF-β reduction; well tolerated.
- Expects to complete initial phase of both cancer studies by early 2024; plans to submit IND for HCW9302 by end of 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1828673/000095017023063348/0000950170-23-063348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1828673/000095017023063348/hcwb-20231114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-063348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer